Investor Overview - MiCo Scientific

MiCo is building a delivery platform for gut-focused nutritional formulations, with oncology as the first use case.

The first use case addresses a practical problem: maintaining intake, tolerance, and supplement usability during demanding care routines.

This page covers the problem, the technology, early validation, commercial logic, and the milestones for the current seed round.

See validation Request the deck

92% patient willingness to buy

2 pilot hospitals in discussion

85% probiotic viability at 6 months

Current financing opportunity

Active seed round targeting €1M

Open now

The round is structured to fund a 12-month execution window focused on clinical pilots, regulatory progress, early commercial traction, and operating capacity.

Runway

12 mo

Focus

Pilots

Goal

Scale proof

Why this is investable

+Focused oncology unmet need
+Platform extension potential
+Founding team with technical depth

What this round unlocks

1Clinical pilots at 2 hospital sites
2Regulatory progress and documentation
3Early commercial traction and operating capacity

Why this company, why now, why this market

A specific first market with broader platform potential

MiCo starts with a specific first market, a differentiated product architecture, and a platform logic that can extend once the first use case is validated and scaled.

Why this company

A credible team building around a specific unmet need

MiCo combines formulation science, microbiology, clinical partnership building, and finance discipline in one founding group. The company is not importing a generic supplement playbook into oncology.

+Founder-led scientific and commercial execution
+Academic and accelerator traction already visible
+IP and platform thinking built in from the start

Why now

Supportive care remains under-served while patient expectations rise

Oncology is not only about tumor response. Treatment tolerance, recovery, gut function, and quality of life increasingly matter to patients, clinicians, and care pathways. MiCo is entering at that intersection.

+20M new cancer cases annually, rising materially over time
+2 in 3 oncology patients experience GI side effects
+Direct patient demand and institutional interest can emerge in parallel

Why this market

A large recurring need with room for category definition

There is clear patient pain, recurring use across treatment phases, and a category gap between clinical nutrition, supportive care, and everyday supplement behavior. MiCo can shape that position rather than compete only on shelf noise.

+Three treatment phases create repeat-use logic
+Consumer and institutional channels can coexist
+Future platform expansion remains possible after oncology proof

Platform logic in one line

One delivery base, three oncology-stage formulations, and an extension path into adjacent high-need nutrition segments once the first wedge is proven.

Why this product and platform

LipoBiomix® is a delivery technology — Insipio+, Fortis+, and Renovo+ are its first products

The product story works because the platform story underneath it is coherent: a liquid lipid micro-matrix that maintains probiotic viability, phase-specific formulations, and the same core delivery logic reusable across future indications — in human nutrition, animal health, cosmetics, and beyond.

Delivery stability

Shelf-stable live-product logic

The current platform demonstrates 85% probiotic viability after 6 months at 4-20 C, supporting a more realistic commercial path than fragile probiotic formats.

Product architecture

Three distinct use scenarios

Three formulations built for different routine patterns: building structure, maintaining continuity when intake is less regular, and rebuilding routine. Each can stand alone or be used in sequence.

Patient usability

A single-shot format for compliance

The shot format aims to reduce the burden of managing many separate supplements at a time when patients already face high treatment complexity.

Future upside

A modular platform beyond oncology

Once the oncology wedge is validated, the same delivery base can support adjacent categories such as post-surgical recovery or antibiotic-related gut disruption.

Looking for the technical rationale behind formula architecture, ingredient roles, and evidence boundaries? The scientific layer is kept on its own page.

Go to Science

What the technology actually is

LipoBiomix® — a liquid lipid micro-matrix designed to solve a hard delivery problem

Most probiotic formats lose viability before use or in transit. Most multi-active formulas require multiple capsules. LipoBiomix® was engineered to solve both problems simultaneously — in a single, ready-to-drink shot.

What LipoBiomix® is

A phospholipid-stabilised liquid matrix that co-encapsulates live cultures and bioactives

The core of the technology is a lipid micro-matrix — a structured phospholipid environment that surrounds and protects live probiotic cells alongside omega-3 fatty acids, vitamins, and prebiotic fibre. This matrix acts as a protective shell during shelf storage and GI transit, keeping cultures viable at counts that matter.

The result is a shelf-stable, liquid, ready-to-drink format with 85% probiotic viability maintained at 6 months (4–20°C) — a level that most liquid probiotic formats cannot achieve without refrigeration or stabilisers that compromise formulation flexibility.

Why this matters technically

Co-delivery of multiple actives
Probiotics, prebiotics, omega-3s, and vitamins travel in the same matrix — eliminating the compliance burden of multiple separate supplements.
Ambient-range shelf stability
Viable at 4–20°C for 6 months — viable in normal pharmacy, hospital, or home conditions without cold-chain logistics.
Modular formulation logic
The delivery base is separable from the active payload — the same matrix can carry different ingredient combinations for different indications, populations, or product categories.

IP position

2 patents pending — PCT filed

Two PCT patent applications cover the core formulation architecture and the delivery matrix composition. PCT status enables priority in EU and key international markets — providing a meaningful IP lead time while MiCo scales its first commercial products.

Validated performance data

85%

probiotic viability at 6 months

25B

CFU per shot

4–20°C

storage range (no cold chain)

ingredients co-delivered per shot

10 months

probiotic stability at 20°C (for now)

Data from internal formulation testing. Product-level clinical data generation is the planned next step, funded in part by this seed round.

Why this IP is defensible

The barrier to replication is not the ingredient list — it is the specific matrix composition and the manufacturing process that achieves ambient-stable co-delivery at clinically relevant CFU counts. That process is what the patents cover.

Platform scope — beyond the first product line

LipoBiomix® is a delivery technology — oncology nutrition is where it starts, not where it ends

The same modular matrix that carries oncology-phase nutrition can carry different payloads for different high-need populations. The oncology wedge comes first — because it is the clearest unmet need, the most demanding technical context, and the strongest proof of platform capability.

Current focus

Human nutrition — oncology

Insipio+, Fortis+, and Renovo+ are the platform's first commercial expression. The oncology context provides the highest-need validation environment and the clearest path to institutional distribution.

Stage: In market · Seed round now

Future application

Animal nutrition

Veterinary probiotic and nutritional supplement markets follow similar delivery logic: live cultures, ambient stability, and high-compliance format. The LipoBiomix® matrix applies directly to companion animal and livestock gut-health applications.

Stage: Post oncology proof point

Future application

Cosmetics & skincare

Probiotic and lipid-based active delivery in topical formats is a growing area of cosmetic science. The LipoBiomix® matrix — already designed to protect live cells across a lipid-water interface — translates naturally to topical co-delivery of actives with skin barrier support.

Stage: Post oncology proof point

Future application

Agriculture

Soil and plant-microbiome applications require stable microbial delivery into challenging environments — exactly the problem LipoBiomix® was designed to solve. Bio-stimulant and soil-inoculant markets represent a longer-horizon adjacency with strong IP leverage.

Stage: Longer-horizon opportunity

Investment framing

The first use case is specific: gut-focused nutrition for people going through demanding care routines. Oncology provides the proof point — a real clinical context where delivery, usability, and tolerability are the constraints that matter. The platform logic extends from there, but the investable story today is that first use case, executed well.

Talk to the team

What has already been validated

Early proof exists across demand, platform behavior, and clinician interest

MiCo is still early, but the current story is not purely hypothetical. The company has already gathered signals that justify advancing into the next de-risking phase.

92%

Patient willingness to buy

Survey of 54 oncology patients and caregivers across the EU indicates strong purchase intent and points to GI support as a major unmet need.

Hospitals in pilot discussion

Oncology departments in Germany and Poland have expressed interest in structured pilots, creating a path toward first institutional real-world use.

Specialist endorsements

Specialist support for the concept already exists, giving MiCo early validation that the problem framing resonates beyond direct-to-consumer language.

85%

Platform viability at 6 months

The current shelf-stability result supports the credibility of the delivery system and helps differentiate MiCo from weaker live-product formats.

Validated today

The core story is already supported by multiple signal types

Demand signal: patients and caregivers show willingness to purchase a product specifically framed around oncology-related GI support.
Clinical signal: pilot interest and specialist endorsement indicate the concept can be discussed inside care environments.
Platform signal: delivery viability and formulation logic suggest there is real technical substance beneath the brand story.

What remains to be de-risked

The next 12 months need to convert promise into repeatable proof

Pilot outcomes: MiCo still needs real-world usage data and stronger institutional validation from structured pilot work.
Regulatory and channel execution: the company must progress FSMP-related execution and show that commercial channels can be built efficiently.
Repeat purchase economics: early demand signal is encouraging, but repeat behavior and cohort quality still need to be shown.

Milestone plan

The near-term roadmap is designed to prove execution, not just generate narrative

The financing story is strongest when tied to specific de-risking steps. MiCo's next phase is about turning early validation into pilot-backed, commercially credible momentum.

Stage 1 - Current

Oncology core line in market-ready form

Three phase-specific SKUs, direct ordering workflow, a visible scientific rationale, and the first set of market and clinical signals already in place.

Stage 2 - Next

Pilot execution and specialist-backed usage data

Structured work with oncology departments in Germany and Poland should provide the next layer of real-world validation and stronger institutional credibility.

Stage 3 - Scale-up

Regulatory and commercial channel expansion

The company then needs to widen access through institutional relationships, distribution partners, and a more repeatable commercial engine.

Stage 4 - Platform upside

Adjacency expansion after the wedge is proven

Only after oncology execution is materially de-risked does the platform extension story become investable in adjacent gut-support use cases.

The page intentionally avoids publishing detailed cap table or valuation mechanics. Those materials can be shared selectively after an introductory conversation and mutual fit check.

Current financing opportunity

Seed round targeting €1M

The round is intended to fund a 12-month path from early signal to stronger execution proof, rather than simply extend runway.

Primary use of funds

Commercial launch work, channel development, and early market traction.

Clinical and regulatory

Pilot execution, specialist engagement, and regulatory progression around the product pathway.

Operating capacity

Selective team build-out, execution support, and the infrastructure needed to scale responsibly.

What investors can request

Introductory deck, milestone plan, scientific support materials, and selective diligence access for aligned investors or strategic partners.

Request investor deck Arrange a call

The team behind the company

Deep technical founders with enough operating credibility to move beyond the lab

The founder set spans chemistry, microbiology, product development, clinical partnership building, and finance - the combination needed for a focused early-stage biotech execution story.

CEO & Co-founder

Natalia Burlaga

MSc. Eng.

→Strategy and clinical partnerships
→PhD candidate in chemical sciences
→R&D background across UTS Sydney, Zentiva, and InoCure
→Winner of EU Sparks and BASF Drive Innovation

CTO & Co-founder

Adam Grzywaczyk

PhD Eng.

→Science innovation and product roadmap leadership
→19 JCR publications in organic and colloid chemistry
→Research background across Sydney and Graz
→Founder with product-building experience

COO & Co-founder

Prof. Wojciech Smulek

PhD Researcher

→Lab-to-product scale-up and quality control
→Associate Professor at Poznan University of Technology
→10+ years in microbiology and bioavailability research
→EU MSCA ORBIS and Bekker NAWA scholar

Advisory CFO

Zofia Rybacka

MSc.

→Financial planning and investor reporting
→Senior Auditor
→Former Financial Analyst
→IFRS postgraduate background and MSc Finance

Next step

Request the investor materials or start a direct conversation

This page is intentionally public and selective. Detailed financing materials, deck access, and diligence information are shared through a direct founder conversation rather than posted openly.

Deck request

Request the investor deck

Best for investors who want the concise company story, current round framing, and milestone logic before going deeper.

Request deck

Selective diligence

Ask about dataroom access

For aligned investors or strategic partners who want a deeper look at validation materials, roadmap detail, and diligence follow-up.

Request access

Direct founder conversation

Arrange a 30-minute call

Best for investors, hospital partners, or distribution partners who want to discuss fit, milestones, or the strategic path in more detail.

Arrange a call

contact@micoscientific.com